Drugs / RO7239958
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03762681 | Dec 2018 → Apr 2020 | hepatitis B virus infection | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7239958 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03762681 ↗ |
| Action | Inhibit | “induces intracellular degradation of PAPD5- and PAPD7-encoding messenger RNAs (mRNAs).” PMID 41186228 ↗ Nov 2025 |
| Modality | Antisense oligonucleotide | “RO7239958, a liver-targeted locked nucleic acid (LNA) antisense oligonucleotide (ASO), induces intracellular degradation of PAPD5- and PAPD7-encoding messenger RNAs (mRNAs).” PMID 41186228 ↗ Nov 2025 |
| Route | Subcutaneous | “single ascending subcutaneous doses of RO7239958 (0.1, 0.3, 1.0, or 1.5 mg/kg) or placebo.” PMID 41186228 ↗ Nov 2025 |
| Target | PAPD5 | “RO7239958, a liver-targeted locked nucleic acid (LNA) antisense oligonucleotide (ASO), induces intracellular degradation of PAPD5- and PAPD7-encoding messenger RNAs (mRNAs).” PMID 41186228 ↗ Nov 2025 |
| Target | PAPD7 | “RO7239958, a liver-targeted locked nucleic acid (LNA) antisense oligonucleotide (ASO), induces intracellular degradation of PAPD5- and PAPD7-encoding messenger RNAs (mRNAs).” PMID 41186228 ↗ Nov 2025 |